Loading news...
New York, New York--(Newsfile Corp. - February 10, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific Corporation") concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER Y.
Oppenheimer Asset Management Inc. lifted its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 84.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 208,429 shares of the medical equipment provider's stock after purchasing an additional 95,402 shares during
New York, New York--(Newsfile Corp. - February 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BOSTON SCIENTIFIC CORPORATION (BSX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to disc.
On Wednesday, Boston Scientific (BSX) experienced a loss of nearly one-fifth of its market capitalization in a single trading session. The stock finished at $75.50, reaching a 52-week low, with a volume approximately six times greater than the 3-month average.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 4, 2026, Boston Scientific.
Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market.
Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was marked by a drastic, high-volume liquidation event that quickly erased months of gains.
New York, New York--(Newsfile Corp. - February 5, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Corporation (NYSE: BSX) reported upbeat earnings for the fourth quarter on Wednesday.
Bessemer Group Inc. lowered its stake in shares of Boston Scientific Corporation (NYSE: BSX) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,903,213 shares of the medical equipment provider's stock after selling 16,588 shares during
Boston Scientific Corporation (NYSE: BSX - Get Free Report) hit a new 52-week low during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $77.86 and last traded at $75.5250, with a volume of 8794500 shares traded. The stock had previously closed at $91.62. Specifically, CEO Michael F.
Boston Scientific Corporation (NYSE: BSX - Get Free Report) saw unusually large options trading activity on Wednesday. Traders acquired 23,490 put options on the stock. This represents an increase of 52% compared to the average daily volume of 15,480 put options. Wall Street Analysts Forecast Growth BSX has been the subject of a number of research
Expand NYSE: BSX Boston Scientific Today's Change (-17.50%) $-16.03 Current Price $75.59 Key Data Points Market Cap $136B Day's Range $75.00 - $81.68 52wk Range $75.00 - $109.50 Volume 3.3M Avg Vol 10M Gross Margin 62.57% Boston Scientific (BSX 17.50%), a medical-device maker for interventional specialties, closed Wednesday at $75.50, down 17.59%. The stock fell after Q4 earnings beat expectations, but cautious 2026 guidance and weaker electrophysiology sales reset growth assumptions.
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Total Revenue: $20.74 billion for full year 2025, 19.9% reported growth versus 2024.Q4 Revenue: $5.286 billion, 15.9% reported growth versus Q4 2024.Organic Re
BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.
Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market.